ID   WM278
AC   CVCL_6473
SY   WM-278; WM 278; WC00054
DR   BTO; BTO:0005480
DR   CLO; CLO_0009616
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2809
DR   BioSample; SAMN03471796
DR   CCLE; WM278_SKIN
DR   Cell_Model_Passport; SIDM00975
DR   Coriell; WC00054
DR   Cosmic; 686401
DR   Cosmic; 972271
DR   Cosmic; 1155544
DR   Cosmic; 1995665
DR   Cosmic; 2159427
DR   Cosmic; 2163805
DR   Cosmic-CLP; 1240226
DR   DepMap; ACH-002206
DR   ESTDAB; ESTDAB-077
DR   GDSC; 1240226
DR   GEO; GSM109035
DR   GEO; GSM186479
DR   GEO; GSM186480
DR   GEO; GSM555133
DR   GEO; GSM555172
DR   GEO; GSM1670579
DR   LINCS_LDP; LCL-1262
DR   PharmacoDB; WM278_1671_2019
DR   Progenetix; CVCL_6473
DR   Wikidata; Q54994223
RX   PubMed=2253310;
RX   PubMed=4053039;
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=21343389;
RX   PubMed=23851445;
RX   PubMed=27397505;
RX   PubMed=30894373;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
WW   http://www.rockland-inc.com/Product.aspx?id=51777
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*02:01,26:01; B*13:02,38:01; C*06:02,12:03; DPB1*02:01:02,01:01:02; DQB1*06:03,02:01; DRB1*13:01,07:01 (PubMed=15592718).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for BRAF p.Val600Glu (c.1799T>A) (ClinVar=VCV000013961) (PubMed=16827748; PubMed=23851445; CCLE; Cosmic-CLP; Wistar).
CC   Sequence variation: Gene deletion; PTEN; Zygosity=Hemizygous (Wistar).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.85%; Native American=0%; East Asian, North=0.99%; East Asian, South=2.12%; South Asian=1.13%; European, North=64.04%; European, South=30.87% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-2809; true.
CC   Discontinued: Coriell; WC00054; probable.
ST   Source(s): ATCC; Cosmic-CLP; ESTDAB; Wistar
ST   Amelogenin: X
ST   CSF1PO: 9
ST   D13S317: 12
ST   D16S539: 10,13
ST   D18S51: 12,15
ST   D19S433: 15,16
ST   D21S11: 27,30
ST   D2S1338: 19,25
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 8,10
ST   D8S1179: 12,13
ST   FGA: 19,22
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 18,20
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_6791 ! WM1617
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-01-21; Version: 30
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958;
RA   Rose A.E., Poliseno L., Wang J., Clark M., Pearlman A., Wang G.,
RA   Vega Y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//